Medtech Trends 2026: Strategic Implications for Emerging Markets and the Global South

Executive Summary

The global medical technology (medtech) industry is undergoing profound structural transformation, driven by pricing reforms, changing care delivery models, supply chain realignment, pharmaceutical innovations, and rapid adoption of enabling technologies. While these forces are often analyzed from the perspective of developed economies, they carry significant consequences for emerging markets and the Global South. As public health systems in Africa, Latin America, South Asia, and Southeast Asia work to expand access and build resilience, they must interpret and respond to these trends strategically. This article assesses the development implications of the major medtech trends identified for 2026, with a focus on industrial policy, regional integration, digital inclusion, and the future of healthcare delivery in low- and middle-income countries.

Introduction

Medtech is no longer a niche sector of high-income health systems. Devices, diagnostics, digital tools, and innovative therapies are increasingly central to health development strategies in the Global South. Yet the forces shaping the sector—procurement practices, trade dynamics, technological convergence, and changing patient behavior—are evolving rapidly. For policymakers, development institutions, and investors, understanding these trends is not merely an analytical exercise; it is essential for anticipating shifts in access, affordability, and industrial opportunity. Drawing on Clarivate's Medtech Trends to Watch 2026, this article provides a Global South–centered interpretation of five key developments and their long-term implications for sustainable development.

Background & Context

Clarivate's report identifies five structural forces likely to define medtech markets in 2026. First, mainland China's volume-based procurement (VBP) program is redefining global pricing dynamics, with effects that ripple across multinational strategies and domestic innovation. Second, the migration of procedures from hospitals to outpatient settings is changing how medical technology is adopted and utilized. Third, global trade and supply chain pressures are prompting manufacturers to diversify production and rethink geographic footprints. Fourth, the rapid uptake of GLP-1 receptor agonists is altering patient behavior and reshaping care pathways for metabolic diseases. Fifth, enabling technologies—robotics, imaging, navigation, and digital workflows—are driving a shift toward platform-based competition.

These trends are interconnected and complex, but they also create space for emerging economies to pursue new development pathways in health technology. The Global South is not a passive observer; it is both a market and a potential manufacturing hub, a source of innovation and a testing ground for new care models.

Main Analysis

1. Volume-Based Procurement: Implications for Pricing, Access, and Local Manufacturing

Mainland China's expansion of volume-based procurement represents a significant experiment in using public purchasing power to compress medical device prices while expanding access. For the Global South, this model has direct relevance. Many countries are struggling to balance fiscal constraints with the need to equip public hospitals and clinics. Local procurement reforms, if designed carefully, can emulate China's approach to reduce costs and incentivize domestic production. However, the deeper implication is for global pricing expectations. As anchor prices fall in China, other markets may negotiate similarly, potentially improving affordability but also affecting the viability of certain technologies. Emerging-market governments should study VBP frameworks, adapt them to local contexts, and use them as tools for achieving universal health coverage while nurturing domestic industries.

2. The Shift to Outpatient and Ambulatory Care: Opportunities for Task-Shifting and Decentralized Services

The movement of procedures to outpatient and ambulatory surgical centers (ASCs) is largely a response to cost pressures and patient preference. In the Global South, where hospital capacity is often limited, a similar shift toward lower-cost, decentralized care offers a pragmatic pathway to expand surgical access. Countries can leverage this trend by investing in primary health facilities, training mid-level health workers, and adapting clinical protocols for outpatient management. The ASC model also aligns with the broader agenda of resilient health systems that can function without overburdening tertiary hospitals. For medtech companies, this shift demands products designed for less complex environments—portable, robust, and easy to maintain—which can directly serve rural and peri-urban areas in emerging markets.

3. Supply Chain Pressures and the Case for Regional Manufacturing Hubs

Geopolitical tensions and tariff exposure have exposed the vulnerabilities of concentrated medical device manufacturing. The Global South has long been dependent on imported devices, often from a handful of suppliers. Current supply chain pressures create a strategic opportunity for regional production clusters. Africa, for instance, could become a hub for assembly and final manufacturing of certain devices, building on regional integration initiatives such as the African Continental Free Trade Area. Governments in Latin America and South Asia can similarly incentivize local value creation, moving from assembly to component fabrication and ultimately to full design and production. Such industrialization depends on investment in quality infrastructure, regulatory harmonization, and skills development—areas where development finance institutions and South-South cooperation can play catalytic roles.

4. GLP-1 Therapies and the Governance of Metabolic Health

The global rise of GLP-1 receptor agonists is reshaping treatment paradigms for obesity and diabetes. While these therapies are often discussed in the context of high-income markets, their implications for the Global South are profound. Non-communicable diseases are already leading causes of morbidity in emerging economies, and the demand for effective metabolic care is growing. However, the high cost and limited availability of GLP-1s pose access challenges. Strategic responses might include tiered pricing, technology transfer for generic production, and incorporating metabolic disease management into primary care protocols. Moreover, the indirect effects of GLP-1 adoption—shifts in demand for bariatric devices, diagnostics, and cardiac monitoring—should be anticipated by health planners and local medtech entrepreneurs.

5. Enabling Technologies and Platform-Based Competition: A Digital Leapfrog Opportunity

Robotics, advanced imaging, navigation systems, and digital workflow software are increasingly integrated into clinical practice. These enabling technologies have historically been expensive and concentrated in advanced facilities. Yet the falling cost of computing, cloud connectivity, and open-platform architectures are making them more accessible. For the Global South, this represents a potential digital leapfrog. Countries can adopt point-of-care diagnostic tools, telemedicine platforms, and AI-assisted decision support without replicating the infrastructure of high-income health system. The emergence of interoperable platforms also enables local developers to build on global architectures, fostering innovation ecosystems that are context-specific. Governments and regional bodies should prioritize digital infrastructure and data governance frameworks to maximize these gains.

Development Impact

The medtech trends analyzed above have direct implications for several sustainable development priorities. They affect the availability and affordability of essential health technologies, which underpins all health-related Sustainable Development Goals. They also influence industrialization and technology adoption, as countries seek to build domestic capabilities. The shift to outpatient care and digital platforms could improve health system efficiency and resilience, while supply chain diversification reduces vulnerability to external shocks. Moreover, the focus on metabolic health and GLP-1 therapies addresses a rising burden of NCDs, with long-term economic benefits from preventing disability and premature death. For emerging markets, these trends also affect foreign direct investment patterns and innovation ecosystems, as multinational companies reassess where to produce, sell, and co-develop technology.

Global South Perspective

The Global South is highly heterogeneous, yet common threads emerge. In Africa, the supply chain crisis and VBP lessons underscore the need for regional manufacturing and pooled procurement mechanisms, such as those championed by the Africa Medical Supplies Platform. In Latin America, the shift to outpatient care can support the transformation of health systems that are often fragmented, and the rise of digital health enables cross-border collaboration. In South Asia, the enabling technologies and platform competition can catalyze a vibrant start-up ecosystem, provided that digital infrastructure is expanded beyond urban centers. For Southeast Asia, the combination of medical devices and manufacturing expertise offers a pathway for industrial upgrading.

South-South cooperation and regional development banks have a central role in spreading these lessons. China's procurement reforms, for example, can inform policy dialogue in other emerging economies. Bilateral technology transfer agreements, joint training programs, and harmonized regulatory standards can accelerate the adoption of appropriate technologies. The Global South must not be a passive recipient of medtech innovation but an active participant in shaping its trajectory.

Future Outlook

Over the next five to ten years, the medtech landscape will likely see further consolidation, digitalization, and regionalization. For the Global South, this creates opportunities to leapfrog legacy systems. Artificial intelligence and digital platforms will become embedded in clinical workflows, enabling more efficient and equitable care. Local manufacturing could expand significantly, especially for higher-volume, moderate-complexity products. Climate adaptation and sustainability will also influence device design and packaging, aligning with global climate commitments.

However, challenges remain. Financing for health technology infrastructure, particularly in low-income countries, will require innovative development finance instruments. Regulatory capacity must be strengthened to ensure safety and efficacy without stifling innovation. Digital inclusion is essential to avoid widening disparities. The next decade will be decisive in determining whether the Global South becomes a thriving producer and consumer of medtech or remains on the periphery. Development institutions, governments, and investors must act now to shape an inclusive and resilient health technology ecosystem.

Conclusion

The trends shaping medtech in 2026 are not abstract corporate concerns; they are engines of structural change with wide-ranging development consequences. For the Global South, these dynamics offer a window to advance health systems, build industrial capabilities, and participate in the global economy through innovation and production. Strategic policy responses, enhanced regional cooperation, and targeted investment in digital and physical infrastructure will determine how fully these opportunities are realized. As the world moves toward a more multipolar health technology landscape, the Global South has an unprecedented opportunity to assert its role—not just as a market, but as a partner and innovator.